ALNA Allena Pharmaceuticals NASDAQ Feb 2026 close $0.075, 252M vol: what’s next
ALNA stock closed at $0.075 on Feb 2026 after 252,311,606 shares traded on the NASDAQ in the United States. The session was marked by high volume and volatile price swings between $0.06 and $0.1459, with the stock ending up 3.16% on the day. Traders focused on Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) because the company’s clinical timetable and cash runway drive near-term moves. Meyka AI provides real-time context and model-based views for active traders
ALNA stock: Price action, volume and session snapshot
ALNA stock traded as low as $0.06 and as high as $0.1459 during the session, closing at $0.075 on NASDAQ. Volume hit 252,311,606 shares, well above typical levels and the main reason ALNA made today’s most active list. The intraday range and high turnover suggest speculative positioning and short-term liquidity events.
ALNA stock: Financials and valuation metrics
Allena Pharmaceuticals reported trailing metrics that reflect an early-stage biotech profile. Trailing EPS is -0.64 and the trailing PE is -0.12, underscoring negative earnings. Cash per share is $0.92 and the current ratio is 2.11, indicating short-term liquidity. Price-to-book sits near 0.13, which signals market pricing well below book value. These ratios explain why valuation is driven by pipeline and financing prospects rather than revenue.
ALNA stock: Clinical pipeline, catalysts and sector context
ALNA’s lead program, ALLN-346, targets hyperuricemia and gout in patients with advanced chronic kidney disease. Clinical readouts, regulatory milestones, or partnership news are primary price drivers for ALNA stock. The broader Biotechnology sector in Healthcare has shown selective appetite for enzyme therapeutics, so sector flow and competing trial results will shape sentiment for Allena Pharmaceuticals, Inc. (NASDAQ: ALNA).
ALNA stock: Trading, technicals and risk factors
Technically, ALNA stock shows high volatility and very low price levels, increasing execution risk. The stock’s historical changes include a one-year decline near -81.39% and multi-year drops exceeding -96%, highlighting long-term capital erosion for buy-and-hold investors. Key risks include dilution from equity financings, trial setbacks, and limited float transparency. Traders should expect wide bid-ask spreads and sudden intraday moves.
Meyka AI rates ALNA with a score out of 100 and forecast
Meyka AI rates ALNA with a score out of 100: 62.51 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month baseline price of $0.12 versus the current $0.075, implying an upside of 60.00%. Forecasts are model-based projections and not guarantees.
ALNA stock: Investor takeaways and trading checklist
Short-term traders should monitor clinical newsflow, financing announcements, and intraday volume spikes for ALNA stock. Fundamental investors must weigh cash per share ($0.92) and operating cash outflows against probable dilution. Use position sizing and limit orders given the stock’s volatility and low absolute price. For sector context, see recent biotechnology coverage on MarketBeat and MarketWatch for broader sentiment shifts source source.
Final Thoughts
ALNA stock closed the session at $0.075 on NASDAQ with 252,311,606 shares traded, underlining heavy speculative interest and liquidity-driven moves. Financially, Allena Pharmaceuticals shows negative EPS (-0.64) and conservative liquidity metrics, with cash per share at $0.92 and a current ratio of 2.11. Meyka AI’s forecast model projects a 12-month baseline of $0.12, which implies a 60.00% upside from today’s close; this projection balances clinical milestone potential against dilution risk. Traders should focus on upcoming trial milestones for ALLN-346 and any financing updates. Remember, Meyka AI provides model-driven views but forecasts are not guarantees. For active trading, keep position sizes small, use protective limits, and watch sector flows and regulatory news that can rapidly change ALNA’s outlook
FAQs
What moved ALNA stock today?
ALNA stock moved on unusually high volume of 252,311,606 shares and intraday volatility between $0.06 and $0.1459, driven by speculative trading and attention to Allena’s clinical pipeline and financing considerations.
What is Meyka AI’s view on ALNA stock?
Meyka AI rates ALNA 62.51/100 (B, HOLD) and models a 12-month baseline of $0.12, implying 60.00% upside from $0.075. These are model projections and not investment guarantees.
What financial risks should investors watch for ALNA stock?
Investors should watch potential equity dilution, negative EPS (-0.64), reliance on trial outcomes, and thin liquidity that can widen spreads. Cash per share ($0.92) helps near-term runway but may not avoid future financing.
How can traders manage ALNA stock volatility?
Use small position sizes, limit orders, and stop protections. Monitor clinical announcements, sector news, and volume spikes. Expect wide bid-ask spreads and rapid intraday swings in ALNA stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.